Objective: Functional status and quality of life outcomes in Latin American outpatients with schizophrenia were compared after 12 months of monotherapy treatment with olanzapine, risperidone or typical antipsychotics.
Method: Both outcomes were assessed as part of a prospective, large (N= 7658), international (27 countries), observational study.
Results: from the Latin American subpopulation (N= 2671; 11 countries) are presented.
Objective: To compare the effectiveness of a 12 months antipsychotic monotherapy treatment with Olanzapine, risperidone and an atypical antipsychotic drug in Latin American patients with schizophrenia.
Method: The outcomes of effectiveness and tolerability were evaluated in outpatients with schizophrenia belonging to a large sample (N=7658) in a prospective, international trial carried out in 27 countries. The results for the population of Latin America were presented.